Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies
MedComm · 2024-08 · 5 (8)
DOI: 10.1002/mco2.671 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 28.07.2024. Verfasst von Jun He und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery Jiande Branch of the Second Affiliated Hospital, School of Medicine, Zhejiang University Jiande Zhejiang China. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 442 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Major International Joint Research Programme.
Abstract (Originalsprache)
Antibody–drug conjugates (ADCs) consist of monoclonal antibodies that target tumor cells and cytotoxic drugs linked through linkers. By leveraging antibodies’ targeting properties, ADCs deliver cytotoxic drugs into tumor cells via endocytosis after identifying the tumor antigen. This precise method aims to kill tumor cells selectively while minimizing harm to normal cells, offering safe and effective therapeutic benefits. Recent years have seen significant progress in antitumor treatment with ADC development, providing patients with new and potent treatment options. With over 300 ADCs explored for various tumor indications and some already approved for clinical use, challenges such as resistance due to factors like antigen expression, ADC processing, and payload have emerged. This review aims to outline the history of ADC development, their structure, mechanism of action, recent composition advancements, target selection, completed and ongoing clinical trials, resistance mechanisms, and intervention strategies. Additionally, it will delve into the potential of ADCs with novel markers, linkers, payloads, and innovative action mechanisms to enhance cancer treatment options. The evolution of ADCs has also led to the emergence of combination therapy as a new therapeutic approach to improve drug efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery Jiande Branch of the Second Affiliated Hospital, School of Medicine, Zhejiang University Jiande Zhejiang China.
- Department of Medical Oncology Chongqing University Cancer Hospital Chongqing China.
ORCID-Profile: Yongsheng Li
Förderung
- Major International Joint Research Programme
Zitieren
APA
He, J., Zeng, X., Wang, C., Wang, E., & Li, Y. (2024). Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies. MedComm, 5(8). https://doi.org/10.1002/mco2.671
Vancouver
He J, Zeng X, Wang C, Wang E, Li Y. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies. MedComm. 2024;5(8). doi:10.1002/mco2.671
BibTeX
@article{He2024,
author = {He, Jun and Zeng, Xianghua and Wang, Chunmei and Wang, Enwen and Li, Yongsheng},
title = {Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies},
journal = {MedComm},
year = {2024},
volume = {5},
number = {8},
doi = {10.1002/mco2.671}
}
EUVIMED